![dpp4 vs sglt2 vs glp-1 Comparative effectiveness of inhibitors, receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records sitagliptin [TUSOM | Pharmwiki]](https://www.thelancet.com/cms/10.1016/S2213-8587(23)00171-7/asset/ac74d262-e278-41b2-8d5c-af3229a7e170/main.assets/gr1.jpg)
dpp4 vs sglt2 vs glp-1
Shipping Estimate
dpp4 vs sglt2 vs glp-1 Comparative effectiveness of inhibitors, receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records sitagliptin [TUSOM | Pharmwiki]
USD23.33
USD53.33
Pay in 4 interest-free payments of $5.83 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
![dpp4 vs sglt2 vs glp-1 Comparative effectiveness of inhibitors, receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records sitagliptin [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/dpp4.png?w=600&tok=f9724b)
![dpp4 vs sglt2 vs glp-1 Comparative effectiveness of inhibitors, receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records sitagliptin [TUSOM | Pharmwiki]](https://ars.els-cdn.com/content/image/1-s2.0-S0003426613000188-gr1.jpg)
![dpp4 vs sglt2 vs glp-1 Comparative effectiveness of inhibitors, receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records sitagliptin [TUSOM | Pharmwiki]](https://www.mdpi.com/molecules/molecules-27-03055/article_deploy/html/images/molecules-27-03055-g001-550.jpg)
![dpp4 vs sglt2 vs glp-1 Comparative effectiveness of inhibitors, receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records sitagliptin [TUSOM | Pharmwiki]](https://www.researchgate.net/publication/365675989/figure/fig1/AS:11431281103572721@1669733380925/SGLT2-inhibitor-versus-DPP-4-inhibitor-treatment-selection-model-The-treatment-selection.png)
![dpp4 vs sglt2 vs glp-1 Comparative effectiveness of inhibitors, receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records sitagliptin [TUSOM | Pharmwiki]](https://www.mdpi.com/cells/cells-14-00387/article_deploy/html/images/cells-14-00387-g002-550.jpg)
